MAP-BC: Reliability And Validity Study Of "The Evaluation Tool For Myofascial Adhesions In Patients After Breast Cancer" In Turkish Language

Sponsor
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05923164
Collaborator
(none)
88
1
13
6.8

Study Details

Study Description

Brief Summary

The aim of this observational study is to translate the MAP-BC Evaluation Tool into Turkish by adapting it to Turkish society and to conduct a validity and reliability study in women who have received breast cancer treatment.

The main questions it aims to answer are:
  • Are the same researcher's MAP-BC Evaluation Tool results similar at intervals to detect myofascial adhesions in breast cancer patients in Turkish population?

  • Are the different researchers' MAP-BC Evaluation Tool results similar to detect myofascial adhesions in breast cancer patients in Turkish population?

  • After comparing the results of Turkish version of both POSAS Observer Subscale and MAP-BC Evaluation Tool, is there a sufficient correlation between them?

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) Evaluation Tool
  • Diagnostic Test: Patient And Observer Scar Assessment Scale ( Observer Subscale)

Detailed Description

Breast cancer is the most frequently diagnosed malignancy in all over the world. Breast and axillary surgery, radiotherapy, hormone therapy and chemotherapy treatments may cause upper extremity dysfunction and pain which negatively affect quality of life and daily living activities of breast cancer patients.

Lymphedema, severe pain, decreased range of motion of shoulder joint, axillary web syndrome, myofascial trigger points and myofascial adhesions are the leading causes affecting upper extremity function in patients with breast cancer.

Myofascial dysfunction presents as a problem characterized by trigger points, adhesions, and limitation of myofascial tissue and tissue gliding.

Muscle manipulation during surgery, scar tissue, soft tissue adhesions, adaptive posture development following surgery and radiotherapy induced fibrosis can cause myofascial adhesions. However, there is not sufficient research or tools for the evaluation of scar tissue and adhesions.

Detection, quantitative measurement and scoring of myofascial adhesions in upper extremity dysfunctions after breast cancer treatment are important for both developing target-oriented treatment plan and evaluation of treatment effectiveness (myofascial therapy, physical therapy modalities).

POSAS is an evaluation tool utilized to detect scar tissue and was shown for reliable and valid in patients who have undergone breast cancer surgery. Its reliability and validity study for Turkish population has been done earlier.

A new diagnostic method called MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) has been developed to evaluate scar tissue after breast cancer treatments and to quantitatively measure myofascial adhesions. Its reliability and validity have been proven in various countries, however, it is yet to be tested in Turkey.

The aim of this observational study is to translate the MAP-BC evaluation tool into Turkish by adapting it to Turkish society and to conduct a validity and reliability study in women who have received breast cancer treatment.

Firstly, the original version of MAP-BC will be translated into Turkish and its semantic and conceptual equivalence will be checked. Later it will be finalized by the committee consisting of two translators and four expert physiatrists.

For intra-rater reliability, the same researcher will re-evaluate patients at 14-days intervals.

For inter-rater reliability, 2 different researchers will evaluate the first 15 patients by using POSAS and MAP-BC tools unaware of each other's results. If the outcome of the two researchers evaluation are found in aggreement at a reliable rate, then the study will be continued by a single researcher.

The convergent validity of the Turkish version of MAP-BC will be assessed by comparing the results of Turkish version of both POSAS observer subscale (Patient and Observer Wound Assessment) and MAP-BC. Their correlation will be analyzed.

Study Design

Study Type:
Observational
Anticipated Enrollment :
88 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Reliability And Validity Study Of MAP-BC Evaluation Tool In Turkish Language To Detect Myofascial Adhesions Among Women Under Breast Cancer Treatment
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
May 30, 2024
Anticipated Study Completion Date :
Jul 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Breast Cancer Patients

Patients who had undergone breast cancer surgery, aged between 18-75 years-old

Diagnostic Test: MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) Evaluation Tool
It's a tool to evaluate scar tissues that occured after breast cancer treatment. It quantitatively measures myofascial adhesions. The degree of adhesion is scored for each area at 3 different depth levels (skin, superficial, deep) as a 4-point scale (0: no adhesion - 3: severe adhesion). Axillary scar, breast/mastectomy scar, m. pectoralis region, frontal chest wall, lateral chest wall, axilla and inframammary fold are evaluated separately. Sum of the scores from three levels of each area gives the total score. The minimal total score is: 0 and the maximum total score is 63.

Diagnostic Test: Patient And Observer Scar Assessment Scale ( Observer Subscale)
This assesment tool consists of two different scales evaluated by the observer and the patient.The observer scale rates five variables, which include vascularity, pigmentation, thickness, relief, pliability and surface area, between 1-10 points (1:normal skin). The total score ranges from 5 to 50.

Outcome Measures

Primary Outcome Measures

  1. MAP-BC Evaluation Tool [11 months]

    This tool was developed to evaluate scar tissues that occured after breast cancer treatments. It quantitatively measures myofascial adhesions. The degree of adhesion is scored for each area at 3 different depth levels (skin, superficial, deep) as a 4-point scale (0: no adhesion - 3: severe adhesion). Axillary scar, breast/mastectomy scar, m. pectoralis region, frontal chest wall, lateral chest wall, axilla and inframammary fold are evaluated separately. Sum of the scores from three levels of each area gives the total score. The maximum score is 63. In Breast cancer patients, the inter-rater reliability of the detection of myofascial adhesions by palpation has been reported good to excellent.

  2. POSAS [11 months]

    This assesment tool consists of two different scales evaluated by the observer and the patient. Its validity and reliability have been proven for the detection of scar tissue in patients who have undergone breast cancer surgery. The observer scale rates five variables, which include vascularity, pigmentation, thickness, relief, pliability and surface area, between 1-10 points (1:normal skin). The total score ranges from 5 to 50. The Turkish version of POSAS, whose validity and reliability studies were conducted, will be used in our study.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No

Inclusion Criteria

  • Breast cancer patients aged between 18-75 years who had undergone breast surgery providing a written consent to participate in the study

Exclusion Criteria

  • Patients who do not agree to participate the study

  • Patients with active skin disease/infection which limits physical examination (palpation)

  • Patients with a secondary breast cancer and/or metastasis

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sultan 2. Abdulhamid Han Training and Research Hospital İstanbul Kadıköy Turkey

Sponsors and Collaborators

  • Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

Investigators

  • Principal Investigator: Yeliz Bahar Özdemir,

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yeliz Bahar Ozdemir, Associate Professor, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
ClinicalTrials.gov Identifier:
NCT05923164
Other Study ID Numbers:
  • 23/337
First Posted:
Jun 28, 2023
Last Update Posted:
Jun 28, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yeliz Bahar Ozdemir, Associate Professor, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 28, 2023